How is the 340B Program Affecting Your Organization?
Historically, manufacturers have been challenged by some of the 340B program nuances and, with the expansion of the Medicaid Drug Rebate program under Affordable Care Act (ACA), manufacturers are likely to see the following challenges grow in volume.
• Accurate accounting from Covered Entities (CE) for refund payments
Health Resources and Services Administration (HRSA) has increased scrutiny around the 340B program and are conducting more targeted audits, CEs are performing internal audits to better understand any non-compliance and are taking steps to “self disclose’ non-compliance activity and proactively sending refund payments to manufacturers. Do you know how to account for the refunds?
• Avoid duplicate payments (340B pricing & Medicaid Rebates) to Covered Entities
The 340B program prohibits duplicate discounts and CEs must have a process in place to prevent duplicate discounts (double dip). Are you paying twice?
• “GPO Prohibition†for selective Covered Entities
Disproportionate share hospitals (DSH) and other selective facilities types participating in 340B may not “obtain covered outpatient drugs through a group purchasing organization (GPO) or other group purchasing arrangement.†Are you having membership woes?
If you are seeking to better understand the impact the 340 B program has on your organization and gain realistic approaches to managing these challenges, please register for this webinar.
Presented by
Steve Medina,
VP, Managed Markets Services
Mr. Medina has led the Covance Managed Market Services business since, July 2012. He has been a consultant for 24 years, 20 of them with healthcare manufacturing, specializing in on-going service solutions (system and business processing), account management, and systems implementation. Mr. Medina has extensive experience with contract management and sales and marketing.
Stephanie Palmer-Willis,
Director, Managed Markets Services
Stephanie Palmer-Willis joins Covance with over 20 years combined leadership in pharmaceuticals managed markets and MCO Provider Relations. Prior to joining Covance, Ms. Palmer-Willis worked in a managerial role for an audit and overpayment recovery firm where she led a team of auditors in identifying and recovering millions of dollars in overpayment made to hospitals and providers.
